NCT03841110 - FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Advanced Solid TumorsLymphomaGastric CancerColorectal CancerHead and Neck CancerSquamous Cell CarcinomaEGFR Positive Solid TumorHER2-positive Breast CancerHepatocellular CarcinomaSmall Cell Lung CancerRenal Cell CarcinomaPancreas CancerMelanomaNSCLCUrothelial CarcinomaCervical CancerMicrosatellite InstabilityMerkel Cell Carcinoma

Interventions

DRUG

FT500

FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy

DRUG

Nivolumab

Immune Checkpoint Inhibitor

DRUG

Pembrolizumab

Immune Checkpoint Inhibitor

DRUG

Atezolizumab

Immune Checkpoint Inhibitor

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

IL-2

Biologic response modifier

Trial Locations (4)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

77030

MD Anderson Cancer Center, Houston

92093

UCSD Moores Cancer Center, San Diego

07601

Hackensack University Medical Center/John Theurer Cancer Center, Hackensack